You don’t have products yet

View Products

BioGenex Anti-PD-L1: A key biomarker in Non-small cell lung cancer diagnostics

Blog: BioGenex Anti-PD-L1: A key biomarker in Non-small cell lung cancer diagnostics

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC starts when the cells lining the lungs become abnormal and grow rapidly, forming a tumor mass. It accounts for about 85 out of every 100 cases of lung cancer. Unlike small cell lung cancer (SCLC), NSCLC grows more slowly but often spreads to other parts of the body by the time of diagnosis.

BioGenex offer PD-L1 (Programmed death ligand 1), potential biomarker associated with NSCLC. It acts as valuable biomarker for Immunotherapeutic studies in lung cancer, particularly in NSCLC. PD-L1, also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is an immunoglobulin-like type I transmembrane glycoprotein that acts as a ligand for programmed death 1 (PD-1). PD-L1 is a transmembrane protein expressed on various cell types viz., T cells, B cells, dendritic cells, and monocytes, including tumor cells. It is a critical factor in infection and disease progression of human immunodeficiency virus, sepsis, and tuberculosis. When PD-L1 interacts with its receptor PD-1, it delivers inhibitory signals to activated B cells and T cells, helping to maintain the balance between effective immunity, tolerance, and immunopathology. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. Additionally, PD-L1 serves as a predictive biomarker for response to immune-checkpoint inhibitors such as anti-PD-1 (e.g., pembrolizumab, nivolumab, durvalumab) or anti-PD-L1 (e.g., atezolizumab, avelumab) antibodies in cancer treatment. Immunotherapeutic drugs targeting the PD-1/PD-L1 pathway have shown promise in treating various cancers, majorly in lung cancer. Therefore, at the time of lung cancer diagnosis, all patients undergo PD-L1 testing. Simple immunohistochemical (IHC) staining helps to determine the percentage of PD-L1-expressing cells in the tumor.

Considering above facts, BioGenex presents Anti-PD-L1 antibody for IHC diagnosis with clean and crisp results outcome. It serves as an essential biomarker in lung cancer diagnostics across the globe. BioGenex offers ready-to-use (RTU) & concentrated forms of antibodies for both manual & automated systems which are best-in-class for clinic-pathological diagnosis & drug discovery. It enables pathologists & clinicians to precisely diagnose and improve life expectancy.

Subscribe to our newsletter

Don't miss out on the latest news, exclusive updates, and special offers.

Do you have questions? Contact Us